Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers
- The Univ. of Texas MD Anderson Cancer Center (MDACC), Houston, TX (United States); Chiba Univ., Chiba (Japan)
- The Univ. of Texas MD Anderson Cancer Center (MDACC), Houston, TX (United States)
- MDACC, Houston, TX (United States)
- Univ. of Puerto Rico-Mayaguez, Mayaguez (Puerto Rico)
- Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
- The Univ. of Texas MD Anderson Cancer Center (MDACC), Houston, TX (United States); Hokkaido Univ. Graduate School of Medicine, Sapporo (Japan)
- Catholic Univ. of the Sacred Heart, Rome (Italy)
Even though hyperthermia is a promising treatment for cancer, the relationship between specific temperatures and clinical benefits and predictors of sensitivity of cancer to hyperthermia is poorly understood. Ovarian and uterine tumors have diverse hyperthermia sensitivities. Integrative analyses of the specific gene signatures and the differences in response to hyperthermia between hyperthermia-sensitive and -resistant cancer cells identified CTGF as a key regulator of sensitivity. CTGF silencing sensitized resistant cells to hyperthermia. CTGF small interfering RNA (siRNA) treatment also sensitized resistant cancers to localized hyperthermia induced by copper sulfide nanoparticles and near-infrared laser in orthotopic ovarian cancer models. Lastly, CTGF silencing aggravated energy stress induced by hyperthermia and enhanced apoptosis of hyperthermia-resistant cancers.
- Research Organization:
- Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
- Sponsoring Organization:
- USDOE
- Grant/Contract Number:
- AC05-76RL01830
- OSTI ID:
- 1339834
- Report Number(s):
- PNNL-SA-120868; 48666; 453040220
- Journal Information:
- Cell Reports, Vol. 17, Issue 6; ISSN 2211-1247
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Similar Records
Decreased expression of RNA interference machinery, Dicer and Drosha, is associated with poor outcome in ovarian cancer patients
UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis